RB1 (RB Transcriptional Corepressor 1)

Conversely, in prostate adenocarcinoma models, DNMT1 deletion leads to de-repression of neuroendocrine lineage genes with a loss of H3K27me3 marks. Our findings reveal a functional interplay between two repressive epigenetic machineries that mediates lineage plasticity in prostate cancer.

TP53, PTEN, and RB1 mutations were linked to inferior overall survival in LuPSMA-treated patients and may serve as prognostic biomarkers. Prospective validation is required to establish their predictive value.

RNA analysis confirmed retention of intronic sequence (exonization), leading to unstable mRNA and/or truncated RB protein. This variant and the associated family history add to the existing body of literature to improve diagnostic genetic testing, clarify inheritance risks, and improve long-term outcomes for retinoblastoma patients.

Compared to normal epidermis, AK and SCCis exhibited increased Rb and p53 expression, whereas MCCis demonstrated loss of expression of both tumor suppressors. These findings suggest that dual downregulation of Rb and p53 may drive select cases of MCCis in sun-damaged skin.

Transcriptomic analyses of Egr1-deficient tumors suggested immune dysregulation, including heightened inflammation and potential markers of T cell exhaustion in the tumor microenvironment. These findings indicate that Egr1 may play a role in suppressing tumor growth through modulating immune dynamics, offering new insights into the interplay between tumor progression and immune regulation in lung adenocarcinoma.

Tumor responses to platinum etoposide versus other chemotherapy regimens were used in a pooled analysis with published study data...Prior studies on association of RB1 status with differential response to chemotherapy regimens had contrasting results. Overall, we find that RB1 loss assessed via immunohistochemistry is a poor prognostic factor for advanced stage LCNEC, and therefore may aid in identification of carcinomas likely to have small cell carcinoma-like behavior.

We observed no evidence of established stress-induced premature or replicative senescence in drug-resistant epilepsy patients. However, elevated proinflammatory cytokines and high p21/p16 expression in the drug-resistant group may suggest ongoing seizures cause cellular stress which could increase susceptibility to senescence in drug-resistant pediatric epilepsy patients over time.

Recurrent insertions were located near cancer-associated genes, including RB1, NEDD4, FTO, LAMA2, NOD1, and KCNB2, implicating LINE-1 activity in cis-regulatory remodeling of oncogenic pathways. Together, these findings indicate that LINE-1 transcript heterogeneity in NSCLC is shaped by host genomic architecture and conserved functional hotspots, providing new insights into the mechanisms of genetic and epigenetic dysregulation associated with LINE-1 retroelements.

Future research should focus on biomarker-driven strategies, including combinations to optimize outcomes. These insights may refine clinical guidelines, advocate for personalized treatment algorithms, and stimulate research into resistance mechanisms, ultimately improving care for BRCA-mutated BC patients.

Collectively, our findings suggested that the downregulation of RB1 significantly influences the morphology of LUAD by facilitating EMT and nuclear abnormalities through HDAC1-mediated deacetylation of lamin A/C. Future research should prioritize the development of targeted therapies aimed at restoring RB1 function or inhibiting HDAC1 to mitigate cancer progression, thereby enhancing patient stratification and treatment strategies in TKI-resistant LUAD.

Providing this standard of care requires consistent practice patterns and collaboration between diagnostic laboratories and tertiary retinoblastoma centers. We describe two cases that highlight the importance of timely and accurate RB1 genetic testing and identification and clinical evaluation of at-risk family members, to optimize outcomes for individuals with hereditary retinoblastoma.

The B-ALL patients with concurrent RB1 and IKZF1 deletions had worse outcomes compared to cases without any of these deletions. The RB1 deletion increased the risk of early events in patients with the IKZF1plus profile.